PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Mipsagargin (G-202), a thapsigargin-based prodrug designed to target tumor neovascular tissue, has shown promising properties in Phase II clinical trials [PMID:25065587, PMID:26429715, PMID:39363839].
Methanolic leaf extract (2g/kg) increased survival time (>18h) and showed recovery of histological damage in envenomed mice [PMID:28993279].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 25856061 (2015) — Thapsigargin--from Thapsia L. to mipsagargin. · Molecules (Basel, Switzerland)
- 2.PMID: 25065587 (2015) — Targeting thapsigargin towards tumors. · Steroids
- 3.PMID: 15387637 (2004) — Tethered lipids from Thapsia garganica. · Journal of natural products
- 4.PMID: 28993279 (2018) — Anti-scorpion venom activity of Thapsia garganica methanolic extract: Histopathological and biochemical evidences. · Journal of ethnopharmacology
- 5.PMID: 31563960 (2020) — Exploring evolutionary theories of plant defence investment using field populations of the deadly carrot. · Annals of botany